Trial record 14 of 77 for:    Emphysema: Clinical Trials

Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2005 by Royal Brompton & Harefield NHS Foundation Trust.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Royal Brompton & Harefield NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT00129350
First received: August 10, 2005
Last updated: September 6, 2005
Last verified: August 2005
  Purpose

At present, a specific community based rehabilitation programme for lung or heart-lung transplant recipients does not exist. 160 hospitals throughout the United Kingdom (UK) offer pulmonary rehabilitation programmes. The programmes operate under evidence-based guidelines as outlined by the Chartered Society of Physiotherapy. Increasing evidence shows that rehabilitation programmes help improve performance, exercise endurance, and quality of life; and reduce symptoms and demand on health-care resources. This study proposes to compare the outcomes of lung and heart-lung transplant patients attending local pulmonary rehabilitation against others receiving the Trust's current document-based programme. The study is a randomized controlled trial:

  • Control Arm: Those patients randomized to the 'control' arm will receive the Trust's standard rehabilitation programme that consists of an information pack supplied upon discharge. They will then complete and undertake the following tests: Short-Form 36 (SF 36; version 2) Questionnaire, Chronic Respiratory Questionnaire (CRQ-SR), Incremental Shuttle Walk Test and Spirometry forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC). The patient will follow the information contained in the information pack and the above tests and questionnaires will be repeated 6 months post discharge.
  • Experimental Arm: A patient who is randomized to the 'experimental' arm will be asked to complete the following tests upon discharge: Short-Form 36 (SF 36; version 2) Questionnaire, Chronic Respiratory Questionnaire (CRQ-SR), Incremental Shuttle Walk Test and Spirometry FEV1 and FVC. Three months post discharge, the patient will be enrolled into a local pulmonary rehabilitation programme. The programme is typically structured to last 6-12 weeks. The above tests and questionnaires will be repeated 6 months post discharge.

To measure the effectiveness of either the information pack or the rehabilitation programme the following endpoints will be subjected to analysis in both the experimental and the control group:

  • Short-Form 36 Questionnaire;
  • Chronic Respiratory Questionnaire;
  • Incremental Shuttle Walk Test;
  • Borg Scale;
  • Spirometry FEV1 and FVC;
  • Hospital re-admission rates and mortality rates.

The undertaking of a multidisciplinary-led programme of rehabilitation facilitates a better quality of life than a document-based rehabilitation programme in lung and or heart-lung transplant out-patients.

The aim of the study is to construct an optimal programme of rehabilitation in lung or heart-lung patients.


Condition Intervention Phase
Emphysema
Alveolitis, Fibrosing
Cystic Fibrosis
Bronchiectasis
Lung Diseases
Procedure: Pulmonary rehabilitation programme
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Assessment of Patient Outcomes Following a Rehabilitation Programme for Patients Who Have Received Lung or Heart-Lung Transplant - a Randomised Controlled Trial

Resource links provided by NLM:


Further study details as provided by Royal Brompton & Harefield NHS Foundation Trust:

Primary Outcome Measures:
  • Exercise Shuttle Test (metres completed)

Secondary Outcome Measures:
  • Borg score
  • Quality of life: SF-36 and Chronic Respiratory Questionnaires
  • Spirometry
  • Hospital re-admission rates
  • Organ rejection

Estimated Enrollment: 60
Study Start Date: September 2004
Estimated Study Completion Date: February 2008
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients who have undergone either a lung or heart-lung transplant.
  • Fit for discharge from the Transplant Unit's Intensive Care Unit.
  • > 18 years of age.

Exclusion Criteria:

  • Patients under 18 years of age.
  • Patients unable to understand or comprehend the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00129350

Contacts
Contact: MICHAEL G PREEDY, BSc Econ 02073528121 ext 2172 M.Preedy@rbh.nthames.nhs.uk
Contact: CHRISTOPHER THEAKER 02073528121 ext 8464 C.Theaker@rbh.nthames.nhs.uk

Locations
United Kingdom
Harefield Hospital Recruiting
Harefield, United Kingdom, UB96JH
Principal Investigator: MICHAEL G PREEDY, BScEcon         
Sponsors and Collaborators
Royal Brompton & Harefield NHS Foundation Trust
Investigators
Principal Investigator: MARTIN CARBY Royal Brompton & Harefield NHS Foundation Trust
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00129350     History of Changes
Other Study ID Numbers: 04-069, 2004NU005B
Study First Received: August 10, 2005
Last Updated: September 6, 2005
Health Authority: United Kingdom: National Health Service

Keywords provided by Royal Brompton & Harefield NHS Foundation Trust:
End Stage Fibrotic Lung Disease

Additional relevant MeSH terms:
Emphysema
Pulmonary Emphysema
Bronchiectasis
Cystic Fibrosis
Fibrosis
Lung Diseases
Idiopathic Interstitial Pneumonias
Pulmonary Fibrosis
Bronchial Diseases
Respiratory Tract Diseases
Pancreatic Diseases
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes
Lung Diseases, Interstitial

ClinicalTrials.gov processed this record on July 20, 2014